Zenas BioPharma, Inc. (ZBIO) is gearing up to report data from several of its ongoing studies using its differentiated B-Cell targeting drug obexelimab for autoimmune disorders. In particular, the ...
Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy has transformed cancer treatment by activating T-cells—a type of immune ...
MILAN, June 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting ...
PiNACLE - H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of ...
A collaborative study published in Immunity from the Batista Lab and Liu Lab at the Ragon Institute, together with the Schief Lab at Scripps Research Institute, has uncovered a previously unrecognized ...
GPRC5D is a promising target for MM therapy, present in MM cells but minimally in normal immune cells, correlating with poorer patient outcomes. Strategies for targeting GPRC5D include bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results